Induction of sarcomas by mutant IDH2

Genes and Development

Volumn 27, Issue 18, 2013, Pages 1986-1998

  Lu, Chao ^a,b   Venneti, Sriram ^a   Akalin, Altuna ^c,g   Fang, Fang ^c   Ward, Patrick S ^a,b   DeMatteo, Raymond G ^a   Intlekofer, Andrew M ^a   Chen, Chong ^a   Ye, Jiangbin ^a   Hameed, Meera ^a   Nafa, Khedoudja ^a   Agaram, Narasimhan P ^a   Cross, Justin R ^d   Khanin, Raya ^e   Mason, Christopher E ^c   Healey, John H ^a   Lowe, Scott W ^a,f   Schwartz, Gary K ^a   Melnick, Ari ^c   Thompson, Craig B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Donald B and Catherine C Marron Cancer Metabolism Center   (United States)

^e Bioinformatics Core Zuckerman Research Center   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

2 hydroxyglutarate; Chondrosarcoma; Contact inhibition; Differentiation; DNA methylation; Isocitrate dehydrogenase mutation; Tumorigenesis

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CHONDROSARCOMA; CLINICAL ARTICLE; CONTACT INHIBITION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STEM CELL; TUMOR BIOPSY;

2-HYDROXYGLUTARATE; CHONDROSARCOMA; CONTACT INHIBITION; DIFFERENTIATION; DNA METHYLATION; ISOCITRATE DEHYDROGENASE MUTATION; TUMORIGENESIS;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE; CHONDROSARCOMA; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MUTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84884545211     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.226753.113     Document Type: Article

References (41)

1. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, et al. 2012a. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 8: e1002781.
2. Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, Mason CE. 2012b. methylKit: A comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol 13: R87.
3. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334-343.
4. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, et al. 2011b. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43: 1262-1265.
5. Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y. 2012. Frequent IDH1/2 mutations in intracranial chondrosarcoma: A possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol 29: 201-206.
6. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. 2006. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 1123-1136.
7. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12: 463-469.
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
9. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
10. Gumbiner BM. 2005. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6: 622-634.
11. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
12. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, et al. 2013. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol 15: 57-68.
13. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339: 1621-1625.
14. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
15. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
16. Mikami Y, Ishii Y, Watanabe N, Shirakawa T, Suzuki S, Irie S, Isokawa K, Honda MJ. 2011. CD271/p75(NTR) inhibits the differentiation of mesenchymal stem cells into osteogenic, adipogenic, chondrogenic, and myogenic lineages. Stem Cells Dev 20: 901-913.
17. Mullarky E, Mattaini KR, Vander Heiden MG, Cantley LC, Locasale JW. 2011. PHGDH amplification and altered glucose metabolism in human melanoma. Pigment Cell Melanoma Res 24: 1112-1115.
18. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
19. Oermann EK, Wu J, Guan KL, Xiong Y. 2012. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 23: 370-380.
20. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, et al. 2011. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43: 1256-1261.
21. Reznikoff CA, Brankow DW, Heidelberger C. 1973. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res 33: 3231-3238.
22. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340: 626-630.
23. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, Cairns RA, McCracken S, Wakeham A, Haight J, et al. 2012a. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26: 2038-2049.
24. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, Harris IS, Holmes R, Wakeham A, Haight J, et al. 2012b. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488: 656-659.
25. Schechtman LM. 2012. Rodent cell transformation assays-a brief historical perspective. Mutat Res 744: 3-7.
26. Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, Margueron R, Reinberg D, Green R, Farnham PJ. 2006. Suz12 binds to silenced regions of the genome in a cell-typespecific manner. Genome Res 16: 890-900.
27. Taylor SM, Jones PA. 1979. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17: 771-779.
28. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. 2012. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
29. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
30. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
31. Wang F, Travins J, Delabarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, et al. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340: 622-626.
32. Warburg O. 1956. On the origin of cancer cells. Science 123: 309-314.
33. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308.
34. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
35. Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB. 2012. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31: 2491-2498.
36. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. 2013. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288: 3804-3815.
37. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. 2009. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080.
38. Williams K, Christensen J, Helin K. 2012. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 13: 28-35.
39. Wu H, Zhang Y. 2011. Tet1 and 5-hydroxymethylation: A genome-wide view in mouse embryonic stem cells. Cell Cycle 10: 2428-2436.
40. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
41. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.